Bristol Myers Squibb (BMS) and Chinese biopharmaceutical giant Hengrui Pharma have announced a monumental licensing and collaboration agreement, potentially valued…
Read More
Dr. Marty Makary Resigns as FDA Commissioner Amidst Reports of Presidential Discontent
Dr. Marty Makary has formally resigned from his position as Commissioner of the U.S. Food and Drug Administration (FDA), a…
Read More
Pharma Manufacturing Facility Sales to Outsourcers Signal Growing Industry Demand for Strategic Flexibility
A notable surge in the acquisition of pharmaceutical manufacturing facilities by contract development and manufacturing organizations (CDMOs) has illuminated a…
Read More
ACROBiosystems Enhances Global Licensing for HEK293 Functional Cell Lines to Accelerate Biopharmaceutical R&D
ACROBiosystems has announced a significant upgrade to its global licensing solution for HEK293 functional cell lines, a move poised to…
Read More
FDA Issues Landmark Guidance to Enhance Pregnancy Safety Data for Medications
The US Food and Drug Administration (FDA) has unveiled its comprehensive final guidance for industry on collecting crucial post-marketing safety…
Read More
Cellular Intelligence Licenses Novo Nordisk’s Parkinson’s Cell Therapy Program Following Company’s Strategic Pivot
Seven months after Danish pharmaceutical giant Novo Nordisk officially shuttered its dedicated cell therapy unit in October 2025, a significant…
Read More
Ginkgo Bioworks CEO Jason Kelly Discusses Autonomous Labs and the Future of Biopharma R&D
The landscape of biopharmaceutical research and development (R&D) is undergoing a seismic shift, driven by the integration of advanced robotics…
Read More
The Evolving Role of Vitamin E TPGS in Advanced Parenteral Drug Delivery
For decades, d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS), a derivative of vitamin E, has been a cornerstone in oral drug…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
Merck’s immunotherapy blockbuster, Keytruda (pembrolizumab), maintained its dominant position as the pharmaceutical industry’s leading brand in Fiscal Year 2025, recording…
Read More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion to Bolster Rare Disease and Brain Health Portfolio
Angelini Pharma, a prominent player in the pharmaceutical sector, has announced a definitive agreement to acquire Catalyst Pharmaceuticals for an…
Read More
